U.S. Biotech Stock News

What Insmed’s Recent Stock Performance Signals for Investors Insmed (INSM) shares recently closed at US$149.54 after a period that includes a 15% decline over the past month and a 23% decline over the past 3 months, in contrast with a strong 1 year total return. See our latest analysis for Insmed. While Insmed’s recent 1-month and 3-month share price returns of 15% and 23% declines suggest fading short term momentum, the 1-year total shareholder return of 87.18% and very large 3-year total...

Cloudera has announced significant advancements in Cloud AI by expanding its AI Inference and Data Warehouse with Trino capabilities to on-premises environments, facilitating faster, secure AI deployment and analytics directly from data centers. These enhancements empower enterprises to move from experimentation to production by providing AI with secure, reliable access to data across multi-cloud, edge, and data center environments. The integration of NVIDIA technology allows for scalable,...

Key Insights Significant insider control over AMC Robotics implies vested interests in company growth Shengwei Da owns...

Recent commentary from KeyBanc Capital Markets and RBC Capital Markets has drawn attention to Casey's General Stores (CASY), highlighting stronger prepared foods and beverage trends, steadier grocery margins, and continued fuel and traffic momentum. See our latest analysis for Casey's General Stores. Those stronger prepared foods, beverage and fuel trends have coincided with firm share price momentum, with a 7 day share price return of 5.29%, a 90 day share price return of 22.15%, and a 1...

CVS Health is cutting costs through large scale layoffs in Connecticut and a broad round of store closures across the US. The company is also changing its preferred drug lists to emphasize lower cost prescription options for customers. These steps are part of an enterprise wide effort to adjust to rising medical costs and policy related pressure on revenue. For investors watching NYSE:CVS, these restructuring moves sit against a mixed share price backdrop. The stock closed at $75.77, with a...

Mohawk Industries recently appointed Chief Operating Officer Paul De Cock as interim president of its Flooring Rest of World segment, following a leadership change effective February 5, 2026. This move temporarily reunites De Cock with a business he previously led for a decade, concentrating operational control in an executive deeply familiar with both global and North American flooring operations. With Paul De Cock assuming interim responsibility for Flooring Rest of World alongside his COO...

Earlier this month, CIBC raised its outlook on Agnico Eagle Mines Limited after updating its precious metals forecasts and highlighting stronger copper assumptions, following the company’s third-quarter 2025 results that showed higher gold selling prices and improved profitability versus the prior year. An interesting takeaway is how Agnico Eagle’s ability to convert materially higher realized gold prices into stronger adjusted net income and free cash flow has reinforced confidence in its...

TTM Technologies recently reported past fourth-quarter 2025 sales of US$774.32 million and net income of US$50.69 million, alongside full-year 2025 sales of US$2.91 billion and earnings guidance for first-quarter and full-year 2026 that includes net sales of US$770 million to US$810 million and an expected 15% to 20% sales growth range. An interesting angle for investors is how this combination of sharply higher profitability and management’s confidence in continued sales expansion may...

Merchants Bancorp (NasdaqCM:MBIN) is set to join the S&P SmallCap 600 index following changes driven by TreeHouse Foods related index adjustments. The index addition is tied to corporate actions around TreeHouse Foods and reflects an update in the S&P SmallCap 600 membership. The inclusion recognizes Merchants Bancorp's current profile in public markets and may affect how it appears in index based portfolios. Merchants Bancorp operates as a bank holding company, giving investors exposure to...

Regeneron Pharmaceuticals has reported past full-year 2025 results showing modest revenue and net income growth, completed a US$1.51 billion share repurchase, and highlighted upcoming long-term EYLEA HD data presentations after its recent FDA approval for macular edema following retinal vein occlusion. The combination of reinforcing its ophthalmology franchise with EYLEA HD and returning capital via buybacks underscores how Regeneron is balancing pipeline progress with shareholder-focused...

Strategy Inc recently reported fourth-quarter and full-year 2025 results showing revenue of about US$122.99 million and US$477.23 million respectively, alongside multi-billion-dollar net losses largely tied to its extensive Bitcoin holdings, while continuing to add more Bitcoin even as crypto markets weakened. By funding a fresh 1,142 BTC purchase with the sale of more than 600,000 new shares, the company is deepening both its concentration in a single volatile asset and the dilution faced...

If you are wondering whether Gilead Sciences is offering fair value at today's share price, this article walks through the numbers in a straightforward way so you can judge for yourself. With the stock at US$151.68, recent returns of 6.2% over 7 days, 25.3% over 30 days, 24.7% year to date, 63.3% over 1 year, 92.7% over 3 years and 174.8% over 5 years put a clear spotlight on how the market currently prices the business. Recent attention on Gilead Sciences has been shaped by news around its...

If you are wondering whether Albemarle's current share price reflects its true worth, this article will walk through what the numbers are actually saying about the stock's value. The shares last closed at US$165.76, with returns of 2.8% over 30 days, 15.2% year to date, and 123.5% over 1 year, set against a 2.9% decline over the past week and a 36.0% decline over 3 years. Recent discussion around Albemarle has focused on its role in lithium production and how sentiment toward battery and...

What Coty’s recent performance means for shareholders Coty (COTY) has been on a rough path recently, with the share price showing negative returns over the past week, month, past 3 months, year, and even over the past 5 years. For investors, that kind of stretch naturally raises questions about what is already reflected in the current US$2.55 share price and how the underlying business compares with the stock’s recent performance. See our latest analysis for Coty. At a share price of US$2.55,...

Without a clear single news catalyst, Bank of N.T. Butterfield & Son (NTB) is back on investor radars after a recent stretch of positive share returns that contrast with mixed profit and revenue trends. See our latest analysis for Bank of N.T. Butterfield & Son. The recent move to a US$53.40 share price caps a steady run, with a 30 day share price return of 6.04% and a 90 day share price return of 15.89%. The 1 year total shareholder return of 37.11% and 5 year total shareholder return of...

Why Deluxe Is On Investors’ Radar With no single headline event driving attention today, Deluxe (DLX) is drawing interest largely because of its recent share performance, including a positive move over the past month and past 3 months. See our latest analysis for Deluxe. While Deluxe’s share price slipped 2.5% over the past week, its recent 30 day and 90 day share price returns of 15.6% and 31.5% suggest momentum has been building on top of a 54% one year total shareholder return. If this...

Watts Water Technologies overview after recent share performance Watts Water Technologies (WTS) has drawn fresh investor attention after a period of strong share performance, with the stock recently closing at $319.76 and showing double digit returns over the past month and past 3 months. See our latest analysis for Watts Water Technologies. Recent moves extend beyond the past few weeks, with a 30 day share price return of 11.24% and a year to date share price return of 14.78%. The 1 year...

Precedence Research has released a broad study on AI-driven bioengineering that spotlights Recursion Pharmaceuticals (RXRX) for its AI biology and phenomics platform, highlighting high-throughput drug discovery and growing government funding across the sector. See our latest analysis for Recursion Pharmaceuticals. Despite the attention around AI-driven drug discovery and growing government support for bioengineering, Recursion Pharmaceuticals’ recent share price performance has been weak. The...

National Fuel Gas Company recently reported past first-quarter 2025 results showing revenue of US$651.51 million and net income of US$181.65 million, both higher than the prior-year period, while also confirming its 2026 production guidance of 440 to 455 Bcf and completing a US$118.29 million share repurchase program begun in March 2024. The sharp year-over-year increase in earnings per share from continuing operations, with basic EPS rising to US$1.99, highlights a significant improvement...

Coherent (COHR) just released its latest quarterly results, reporting higher sales and net income along with fresh revenue guidance of US$1.70b to US$1.84b for the upcoming quarter, giving investors more concrete near term expectations. See our latest analysis for Coherent. The latest earnings and revenue guidance arrived alongside strong momentum in Coherent’s shares, with a 1-day share price return of 6.49% and a 30-day share price return of 36.17%. The 1-year total shareholder return is...

Leadership shake up and AI upgrades put Opendoor back in focus Opendoor Technologies (OPEN) is back on investor radars after appointing Kaz Nejatian as CEO, bringing its co-founders onto the board, securing fresh institutional capital, and pushing new AI and marketplace upgrades across its real estate platform. See our latest analysis for Opendoor Technologies. At a share price of $4.94, Opendoor’s 1 month share price return of 32.24% and 3 month return of 47.28% contrast with a very large 1...

Incyte (INCY) is back in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on Zynyz plus platinum-based chemotherapy for the first-line treatment of advanced anal cancer. See our latest analysis for Incyte. The CHMP news comes as Incyte’s share price has been quietly grinding higher, with a 7.5% year to date share price return and a 59.63% total shareholder return over the past year. This hints that momentum has been building...

Applied Digital (NasdaqGS:APLD) has shifted its focus from crypto-mining infrastructure to AI-focused data centers. The company has secured about US$16b in lease contracts over 15 years tied mainly to AI data center capacity. Large new campuses are under construction as part of an aggressive buildout to serve AI workloads. Applied Digital now faces high customer concentration risk, with heavy reliance on CoreWeave as a primary tenant. The company’s debt load has grown materially, creating...

If you are wondering whether MKS at around US$250.60 is still a reasonable entry or more of a hold, you are asking the right question for a stock that has already moved a lot. The share price has seen strong recent returns, with about 9.2% over the past week, 34.7% over the past month, 48.8% year to date, 128.4% over the last year, 158.0% over three years and 51.3% over five years, which can change how the market views both its potential and its risks. Recent company specific news and sector...